OptimizeRx Corp — Director's Dealing 2024

Apr 22, 2024

SEC Form 4/A — Form 4/A

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2023-10-11

Reporting Person: Stelmakh Edward (CFO/COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-11	Common	M	8221	—	Acquired	28034	Direct

Footnotes

F1: This Form 4 as originally filed reported in Table I and Table II a vesting of a restricted stock unit on 10/11/2022. However, this transaction had been previously reported on March 30, 2023. Accordingly, it has been struck from this amended filing.

F2: On October 12, 2023, the Reporting Person inadvertently understated in Table I of Form 4 (the "Original Form 4") the number of shares acquired upon the vesting a restricted stock unit. The correct amount of shares disposed of in connection with such vesting was correctly reported in Table II of the Original Form 4.

F3: As a result of the understatement, the amount reported in the Reported Person's holdings following the reported transaction was also understated. This inadvertent understatement has been corrected in this line of the amended filing. This understatement also affected the holdings reported after subsequent transactions in the Original Form 4 and in subsequently filed Forms 4, but will be corrected in any Forms 4 filed after the date of this amended filing.